Compare PRFX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRFX | CMND |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.9M |
| IPO Year | 2020 | N/A |
| Metric | PRFX | CMND |
|---|---|---|
| Price | $0.89 | $2.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.3K | ★ 209.0K |
| Earning Date | 02-27-2026 | 01-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $1.74 |
| 52 Week High | $6.65 | $64.80 |
| Indicator | PRFX | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 64.91 |
| Support Level | $0.66 | $2.36 |
| Resistance Level | $0.74 | $2.74 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 74.46 | 66.42 |
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.